Bristol Myers Squibb Reports Third Quarter Financial Results for 2023

Reports Third Quarter Revenues of $11.0 Billion



Posts Third Quarter GAAP Earnings Per Share of $0.93 and Non-GAAP EPS of $2.00; Includes Net Impact of Per Share for GAAP and Non-GAAP EPS Due to...

Related Keywords

United States ,Canada ,China ,Athens ,Attikír ,Greece ,Puerto Rico ,Russia ,Ukraine ,Russian Federation ,Neoadjuvant Opdivo ,Bristol Myers Squibb ,Giovanni Caforio ,Christopher Boerner ,Pomalyst Imnovid ,Revlimid Pomalyst ,Drug Administration ,Clinical Research ,European Commission ,Point Therapeutics Inc ,Linkedin ,Securities Exchange ,Bristol Myers Squibb Patient Assistance Foundation ,Twitter ,Mirati Therapeutics Inc ,Pfizer Alliance ,Youtube ,International Intl ,Instagram ,Exchange Commission ,European Commission For Opdivo ,Business Development ,B Drug Pricing Program ,Facebook ,Bristol Myers ,Myers Squibb ,Turning Point Therapeutics ,Turning Point ,New Product ,Includes Puerto ,Bristol Myers Squibb Pfizer Alliance ,Biologics License Application ,Blinded Independent Central ,Priority Review ,New Drug Application ,Prescription Drug User Fee Act ,Breakthrough Therapy Designation ,Psoriasis Area ,Severity Index ,Cell Therapy ,Targeted Protein Degradation ,Mirati Therapeutics ,Billion Dollar Roundtable ,Accepted Accounting Principles ,Nimbus Therapeutics ,Securities Act ,Securities Exchange Act ,Drug Pricing Program ,Russian Federation Ukraine ,Annual Report ,Quarterly Reports ,Current Reports ,Income Taxes ,Earnings Attributable ,Average Common Shares Outstanding ,Common Share ,In Line Products ,Specified Items ,Months Ended September ,Diluted Earnings Attributable ,Statement Regarding Forward Looking ,Markets ,